{{Rsnum
|rsid=2300478
|Gene=MEIS1
|Chromosome=2
|position=66554321
|Orientation=plus
|GMAF=0.2218
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=MEIS1
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 3.6 | 40.2 | 56.2
| HCB | 3.7 | 39.7 | 56.6
| JPT | 2.7 | 42.5 | 54.9
| YRI | 0.0 | 19.7 | 80.3
| ASW | 0.0 | 23.2 | 76.8
| CHB | 3.7 | 39.7 | 56.6
| CHD | 7.3 | 39.4 | 53.2
| GIH | 7.9 | 46.5 | 45.5
| LWK | 0.9 | 24.8 | 74.3
| MEX | 6.9 | 37.9 | 55.2
| MKK | 0.0 | 14.8 | 85.2
| TSI | 3.9 | 50.0 | 46.1
| HapMapRevision=28
}}[[rs2300478]], a SNP located in the [[MEIS1]] gene, has been linked to [[restless legs syndrome]], a common sleep disorder, with an overall odds ratio of 1.78 (CI: 1.52-2.09) for the (G) risk allele {{PMID|17637780}}. The association between this SNP and RLS has been replicated in three European populations, within family lines but not in sporadic cases {{PMID|19279021|OA=1
}}. 

The highest association to [[restless legs syndrome]] is a haplotype consisting of the [[rs6710341]](A) and [[rs12469063]](G) alleles. This haplotype gives rise to an odds ratio of 2.75 (CI: 2.23-3.41) {{PMID|17637780}}. 

Variants in MEIS1 [[rs2300478]], BTBD9 [[rs9357271]], and MAP2K5/SKOR1 [[rs1026732]] confer a significant risk of RLS in a US population. {{PMID|21925394|OA=1
}}

In another study, [[rs2300478]] was not associated with [[attention deficit hyperactivity disorder]] (ADHD). {{PMID|19223043}}

{{GWAS Summary
|SNP=rs2300478
|PubMedID=17637780
|Condition=Restless legs syndrome
|Gene=MEIS1
|Risk Allele=G
|pValue=3.00E-028
|OR=1.74
|95CI=1.57-1.92
}}

{{PMID Auto
|PMID=19223043
|Title=Exploring the genetic link between RLS and ADHD
}}

{{PharmGKB
|RSID=rs2300478
|Name_s=
|Gene_s=MEIS1
|Feature=
|Evidence=PubMed ID:17637780; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions (Initial Sample Size: 401 cases, 1,644 controls; Replication Sample Size: 1,158 cases, 1,178 controls; Risk Allele: rs2300478-G).
|Drugs=
|Drug Classes=
|Diseases=Restless Legs Syndrome
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356677
}}

{{PharmGKB
|RSID=rs2300478
|Name_s=
|Gene_s=MEIS1
|Feature=
|Evidence=PubMed ID:17637780
|Annotation=In replicated GWAS case-control studies of Caucasian(European and French-Canadian) familial and sporadic RLS, the G allele of rs2300478 was significantly associated with Restless Legs Syndrome.
|Drugs=
|Drug Classes=
|Diseases=Restless Legs Syndrome
|Curation Level=Curated
|PharmGKB Accession ID=PA162355626
}}

{{omim
|id=612853
|rsnum=2300478
}}

{{PMID Auto GWAS
|PMID=21779176
|Trait=None
|Title=Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1.
|RiskAllele=G
|Pval=3E-49
|OR=1.6800
|ORtxt=[1.57-1.81]
|OA=1
}}

{{PMID|21925394|OA=1
}}  Association studies of variants in MEIS1, BTBD9, and MAP2K5/SKOR1 with restless legs syndrome in a US population.

{{PMID Auto
|PMID=19126776
|Title=MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels.
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2300478
|overall_frequency_n=29
|overall_frequency_d=128
|overall_frequency=0.226562
|n_genomes=19
|n_genomes_annotated=0
|n_haplomes=21
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

[[Restless Legs Syndrome: Preliminary Research]]

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}